David Risinger

AbbVie Inc (NYSE: ABBV) shares are up 8 percent in one month, despite touching a low of $46.92 on October 22. Morgan Stanley’s David Risinger upgraded the rating on the company from Equal-Weigh to Overweight, while raising the price target from $62 to $73. With an increase in EPS...

Shares in healthcare broadly and biotech specifically have been under pressure over the past one month. Most big biotech stocks are down since September 2. Morgan Stanley analysts have commented on the cash position and pipelines of big biotech companies, against the backdrop of growing...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares have been volatile over the last 5 trading days, down 27 percent since September 22. Morgan Stanley’s David Risinger maintained an Overweight rating on the company. While the company’s shares have plunged on drug pricing...

Shares of Alkermes Plc (NASDAQ: ALKS) have risen more than 33 percent over the past year. Morgan Stanley’s David Risinger has upgraded Alkermes from Underweight to Overweight, while raising the price target from $61 to $85. Risinger believes that negative results has either been...

The share price of Endo International plc - Ordinary Shares (NASDAQ: ENDP) (Endo Health Solutions, Inc.) has declined over 10 percent in the last six months. Morgan Stanley’s David Risinger has downgraded the rating on Endo International from Overweight to Equal-Weight, while lowering...

In a report published Monday, Morgan Stanley analyst David Risinger maintained an Overweight rating on Valeant Pharmaceuticals Intl. Inc. (NYSE: VRX), while raising the price target from $235 to $284. The analyst believes that while the company is expected to continue to see organic growth...

In a report published Monday, Morgan Stanley analyst David Risinger and his team reiterated an Overweight rating on Bristol-Myers Squibb Co (NYSE: BMY) after the National Comprehensive Cancer Network (NCCN) updated its guidelines for the treatment of Non-Small Cell Lung Cancer (NSCLC) to...

In a report published Thursday, Morgan Stanley analyst David Risinger resumed coverage of AbbVie Inc (NYSE: ABBV) with an Equal-weight rating and $72 price target. The analyst believes that the acquisition of Pharmacyclics, Inc. (NASDAQ: PCYC) adds an attractive growth driver for AbbVie. The...

In a report published Monday, Morgan Stanley analyst David Risinger reiterated an Equal-Weight rating on Mallinckrodt PLC (NYSE: MNK), and raised the price target from $106.00 to $127.00. In the report, Morgan Stanley noted, "We are Equal-weight MNK shares. Although we anticipate strong growth...

In a report published Thursday, Morgan Stanley analyst David Risinger downgraded the rating on Alkermes Plc (NASDAQ: ALKS) from Equal-Weight to Underweight, but named a $61.00 price target. In the report, Morgan Stanley noted, "Downgrade from E-W to UW relative to our coverage universe on...

In a report published Thursday, Morgan Stanley analyst David Risinger resumed coverage on Mylan Inc. (NASDAQ: MYL) with an Overweight rating and $67.00 price target. In the report, Morgan Stanley noted, "We believe Mylan's depressed multiple is an over-reaction to uncertain growth prospects (e.g.,...

AbbVie Inc.'s (NYSE: ABBV) $21 billion deal Wednesday to acquire Pharmacyclics, Inc. (NASDAQ: PCYC) will expand its presence in the market for cancer treatments and add to its revenue, an analyst said Thursday. AbbVie changed hands recently down 2.3 percent to $58.85; Pharmacyclics jumped...

In a report published Thursday, Morgan Stanley analyst David Risinger resumed coverage on Endo International plc - Ordinary Shares (NASDAQ: ENDP) with an Overweight rating and $101.00 price target. In the report, Morgan Stanley noted, "We believe investors under-appreciate the durability of Endo's...